Applied Therapeutics, Inc.
Applied Therapeutics, Inc. (APLT) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
aplt · stock forecast · 11 analysts (3M) · FMP · updated Feb 13, 2026
Analyst Rating & Consensus
Based on 11 Wall Street analysts in the past 3 months
Buy
11 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.25
Consensus
$0.25
+142.7% upside
Low
$0.25
Median: $0.25 · Last Close: $0.10
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $0.10 | ↑ 0.63% |
1-day model range: $0.1–$0.1. Peak: $0.1 (+0.63%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · APLT · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-12-03 | Leerink Partners | Downgrade ↓ | Outperform→Market Perform |
| 2025-05-14 | RBC Capital | Maintains | Sector Perform→Sector Perform |
| 2024-12-23 | William Blair | Downgrade ↓ | Outperform→Market Perform |
| 2024-12-20 | RBC Capital | Maintains | Sector Perform→Sector Perform |
| 2024-12-02 | UBS | Downgrade ↓ | Buy→Neutral |
| 2024-11-29 | RBC Capital | Downgrade ↓ | Outperform→Sector Perform |
| 2024-11-29 | Citigroup | Maintains | Buy→Buy |
| 2024-11-29 | Baird | Maintains | Outperform→Outperform |
| 2024-11-27 | Citigroup | Maintains | Buy→Buy |
| 2024-09-19 | Citigroup | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Applied Therapeutics, Inc. (APLT) stock. Of the recent 32 rating actions, 0 were upgrades and 6 were downgrades. 11 analysts currently cover APLT.
Analyst Recommendation Trends
APLT analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$1M
↓ 98.0% YoY
Revenue Next Year
$2M
↑ 66.7% YoY
EPS This Year
$-0.53
EPS Next Year
$-0.43
↓ 19.7% YoY
EPS ForecastReported vs Estimated
Analysts forecast APLT EPS of $-0.53 for the current fiscal year, based on estimates from 2 analysts. The APLT revenue forecast is $1M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The APLT stock forecast is supported by two independent data sources: analyst consensus ratings from 11 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus APLT price target is $0.25 (+142.7% upside), with an analyst consensus of Buy.
The APLT short-term stock prediction for tomorrow is $0.10 (+0.63%).
Applied Therapeutics, Inc. trades on NASDAQ under the ticker APLT. The APLT stock outlook for 2027 is broadly positive, supported by a Buy consensus among 45% of covering analysts.
Frequently asked questions
APLT forecast · 8 questionsAccording to 11 Wall Street analysts, the average 12-month APLT price target is $0.25, with a high forecast of $0.25 and a low of $0.25. The median price target is shown in the chart above when available. This implies +142.7% potential upside from the current price of $0.10.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.